HSA
ENTA icon

Hussman Strategic Advisors’s Enanta Pharmaceuticals ENTA Stock Holding History

Hussman Strategic Advisors’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-10,000
Closed -$955K – 202
2019
Q1 		$955K Hold
10,000
– – 0.23% 155
2018
Q4 		$708K Buy
+10,000
New +$767K 0.17% 178

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Hussman Strategic Advisors's ENTA Position: Q2 2019 in Review

Hussman Strategic Advisors sold out of Enanta Pharmaceuticals (ENTA) in Q2 2019, closing a stake of 10,000 shares — an estimated $955K sold.

Hussman Strategic Advisors first reported a position in ENTA in Q4 2018 and held it in 2 quarters. The position peaked at $955K in Q1 2019. 194 funds tracked by Wall St. Rank hold ENTA as of Q2 2019.

  • Hussman Strategic Advisors reported no remaining Enanta Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Hussman Strategic Advisors sold 10,000 Enanta Pharmaceuticals shares in Q2 2019, an estimated $955K.
  • Hussman Strategic Advisors first reported a position in Enanta Pharmaceuticals in Q4 2018 and held it in 2 quarters.
  • Hussman Strategic Advisors's Enanta Pharmaceuticals position peaked at $955K in Q1 2019.
  • 194 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2019.

Based on Hussman Strategic Advisors's 13F filing for Q2 2019, filed 31 Jul 2019.